TCA
IBB icon

Transcend Capital Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Transcend Capital Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.14M Sell
12,659
-708
-5% -$121K 0.17% 116
2025
Q4 		$2.26M Buy
13,367
+3,045
+30% +$495K 0.17% 118
2025
Q3 		$1.49M Buy
10,322
+1
+0% +$136 0.1% 177
2025
Q2 		$1.31M Sell
10,321
-664
-6% -$81.5K 0.1% 182
2025
Q1 		$1.4M Buy
10,985
+27
+0.2% +$3.66K 0.1% 206
2024
Q4 		$1.45M Buy
10,958
+92
+0.8% +$12.9K 0.1% 192
2024
Q3 		$1.58M Sell
10,866
-41
-0.4% -$5.93K 0.11% 200
2024
Q2 		$1.5M Sell
10,907
-83
-0.8% -$11.1K 0.11% 195
2024
Q1 		$1.51M Buy
10,990
+15
+0.1% +$2.05K 0.12% 178
2023
Q4 		$1.49M Buy
10,975
+497
+5% +$60.6K 0.13% 168
2023
Q3 		$1.28M Buy
10,478
+400
+4% +$50.9K 0.12% 170
2023
Q2 		$1.28M Buy
10,078
+5,839
+138% +$759K 0.12% 177
2023
Q1 		$548K Sell
4,239
-1,605
-27% -$210K 0.06% 275
2022
Q4 		$767K Buy
5,844
+409
+8% +$52.9K 0.08% 225
2022
Q3 		$636K Buy
5,435
+1,124
+26% +$140K 0.07% 247
2022
Q2 		$507K Sell
4,311
-6,114
-59% -$726K 0.05% 294
2022
Q1 		$1.36M Sell
10,425
-10
-0.1% -$1.3K 0.12% 179
2021
Q4 		$1.59M Buy
10,435
+36
+0.3% +$5.57K 0.14% 165
2021
Q3 		$1.66M Sell
10,399
-401
-4% -$67.5K 0.15% 151
2021
Q2 		$1.76M Buy
10,800
+3,103
+40% +$478K 0.25% 99
2021
Q1 		$1.16M Sell
7,697
-231
-3% -$36.7K 0.14% 163
2020
Q4 		$1.2M Sell
7,928
-718
-8% -$103K 0.16% 146
2020
Q3 		$1.17M Buy
+8,646
New +$1.17M 0.21% 101
2020
Q2 		– Sell
-3,258
Closed -$351K – 151
2020
Q1 		$351K Buy
+3,258
New +$375K 0.11% 164

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Transcend Capital Advisors's IBB Position: Q1 2026 in Review

Transcend Capital Advisors reduced its iShares Biotechnology ETF (IBB) stake by 5.3% in Q1 2026, selling an estimated $121K and leaving 12,659 shares worth $2.14M. The position accounts for 0.17% of the portfolio, ranked #116.

Transcend Capital Advisors first reported a position in IBB in Q1 2020 and has held it in 24 quarters since. The position peaked at $2.26M in Q4 2025. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Transcend Capital Advisors held 12,659 shares of iShares Biotechnology ETF worth $2.14M as of Q1 2026.
  • Transcend Capital Advisors sold 708 iShares Biotechnology ETF shares in Q1 2026, an estimated $121K.
  • iShares Biotechnology ETF made up 0.17% of Transcend Capital Advisors's portfolio in Q1 2026, its #116 holding.
  • Transcend Capital Advisors first reported a position in iShares Biotechnology ETF in Q1 2020 and has held it in 24 quarters since.
  • Transcend Capital Advisors's iShares Biotechnology ETF position peaked at $2.26M in Q4 2025.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.